Pricing Log in Create free account
Saturday 17 October 2026 Export KALA’s income statement to Excel — free account

KALA BIO, Inc.

KALA Healthcare Biotechnology

KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million. In the quarter to June 2026, EPS grew 75.1% and free cash flow grew 80.2%, each against the same quarter a year earlier.

0.19 0.00 0.00%
Market cap
$3.7M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
3/9
Altman Z
−11.18
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

KALA BIO, Inc. (KALA) Business Profile

Updated before January 2025

Company Overview

KALA BIO, Inc. (KALA) is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for eye diseases and other related conditions. Founded in 2009, KALA is headquartered in Watertown, Massachusetts, USA. The company was established by a team of scientists and entrepreneurs with a vision to address unmet medical needs in ophthalmology using advanced drug delivery technologies. KALA’s leadership team includes experienced professionals from the pharmaceutical and biotechnology industries, with Mark Iwicki serving as the Chairman and CEO. Under his leadership, KALA has made significant strides in developing and bringing to market transformative therapies for patients.

Core Business Segments

KALA focuses on the development of therapies for ocular diseases, leveraging its proprietary AMPPLIFY® drug delivery technology. The company’s core business segments include:

1. Prescription Ophthalmic Therapies

KALA develops prescription therapies for the treatment of eye diseases, including dry eye disease, inflammation, and post-surgical recovery. Key products include:

  • EYSUVIS® (loteprednol etabonate ophthalmic suspension 0.25%): A corticosteroid designed for the short-term treatment of dry eye disease. EYSUVIS is the first and only FDA-approved therapy for this indication.
  • INVELTYS® (loteprednol etabonate ophthalmic suspension 1%): A corticosteroid for the treatment of post-operative inflammation and pain following ocular surgery. INVELTYS utilizes KALA’s AMPPLIFY® technology to enhance drug penetration into target tissues.

2. Pipeline Development

KALA is actively advancing its pipeline of innovative therapies for other ocular conditions. These include:

  • KPI-012: A novel therapy in development for persistent corneal epithelial defects (PCEDs), a rare and serious condition that can lead to vision loss.
  • Other Preclinical Programs: KALA is exploring additional applications of its AMPPLIFY® technology for the treatment of retinal diseases and other ophthalmic conditions.

Business Model

KALA’s business model is centered around the development, approval, and commercialization of innovative therapies for eye diseases. The company generates revenue through the sale of its FDA-approved products, EYSUVIS and INVELTYS, as well as through potential licensing agreements and partnerships for its pipeline products. KALA’s proprietary AMPPLIFY® technology serves as a key differentiator, enabling the company to develop therapies with enhanced efficacy and safety profiles. By focusing on high-value markets with significant unmet needs, KALA aims to maximize its impact on patient outcomes and shareholder value.

Strategic Direction

KALA is committed to expanding its portfolio of innovative therapies and addressing unmet needs in ophthalmology. Key strategic priorities include:

  • Pipeline Expansion: Advancing the development of KPI-012 and other preclinical programs to address rare and serious ocular conditions.
  • Market Penetration: Increasing the adoption of EYSUVIS and INVELTYS through targeted marketing and education initiatives.
  • Global Expansion: Exploring opportunities to commercialize its products in international markets through partnerships and licensing agreements.
  • Sustainability Goals: Implementing environmentally sustainable practices in its operations and supply chain to minimize its environmental footprint.
  • Innovation: Continuing to leverage its AMPPLIFY® technology to develop next-generation therapies for ocular diseases.

Competitive Landscape

KALA operates in a competitive market, with several established players and emerging companies focusing on ophthalmology. Key competitors include:

  • Allergan (a subsidiary of AbbVie): A leader in ophthalmology with a broad portfolio of therapies for dry eye disease, glaucoma, and other conditions.
  • Novartis: A global pharmaceutical company with a strong presence in ophthalmology through its Alcon division and products like Xiidra® and Lucentis®.
  • Regeneron Pharmaceuticals: Known for its innovative therapies for retinal diseases, including Eylea®.
  • Sun Pharma: A competitor in the post-operative inflammation market with its corticosteroid Durezol®.

KALA differentiates itself through its proprietary AMPPLIFY® technology and focus on addressing unmet needs in ophthalmology.

Risk Factors

KALA faces several risks that could impact its business operations and financial performance, including:

  • Market Dependence: Reliance on the success of EYSUVIS and INVELTYS for revenue generation.
  • Regulatory Risks: Challenges in obtaining regulatory approval for pipeline products.
  • Supply Chain Disruptions: Potential delays or interruptions in the manufacturing and distribution of its products.
  • Competition: Intense competition from established players and new entrants in the ophthalmology market.
  • Financial Risks: Dependence on external funding to support research and development activities.

Recent Developments

KALA has made significant progress in advancing its pipeline and expanding its commercial footprint. Recent developments include:

  • KPI-012 Clinical Trials: Initiation of Phase 2/3 clinical trials for KPI-012 in the treatment of persistent corneal epithelial defects.
  • EYSUVIS Launch: Continued efforts to increase the adoption of EYSUVIS through targeted marketing campaigns and physician education.
  • Partnerships: Exploration of strategic partnerships to expand the reach of its products in international markets.
  • COVID-19 Impact: Implementation of measures to mitigate the impact of the COVID-19 pandemic on its operations and supply chain.

Investment Considerations

Investors considering KALA should weigh the following strengths and risks:

Strengths

  • Innovative AMPPLIFY® technology with broad applications in ophthalmology.
  • FDA-approved products with significant market potential.
  • Strong pipeline of therapies addressing unmet medical needs.
  • Experienced leadership team with a track record of success.

Risks

  • Dependence on a limited number of products for revenue generation.
  • Regulatory and clinical development risks associated with pipeline products.
  • Intense competition in the ophthalmology market.
  • Financial risks related to funding requirements for R&D activities.

Conclusion

KALA BIO, Inc. is a pioneering biopharmaceutical company with a strong focus on addressing unmet needs in ophthalmology. With its innovative AMPPLIFY® technology, FDA-approved products, and promising pipeline, KALA is well-positioned to drive growth and deliver value to patients and shareholders. While the company faces risks related to market dependence and competition, its strategic initiatives and commitment to innovation provide a solid foundation for future success.